BIIB vs RLMD
BIIB: A pioneer in neuroscience and immunology, Biogen is a major biotechnology company focused on addressing high-unmet medical needs in complex diseases like Alzheimer’s, Multiple Sclerosis, and SMA. RLMD: Clinical-stage biotech redirecting toward oncology and neurology with in-licensed chemotherapy delivery and neurosteroid platforms after terminating its lead depression candidate.
Side-by-side fundamentals
| Metric | BIIB | RLMD | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $200.14 | $5.20 | |
| Market cap as of 2026-07-30 | $31.8B | $545M | |
| P/E as of 2026-07-30 | 23.19 | n/a | |
| PEG as of 2026-07-30 | 10.24 | n/a | |
| Net margin as of 2026-07-30 | +13.8% | -500.0% | BIIB higher |
| Gross margin as of 2026-07-30 | +75.5% | +0.0% | BIIB higher |
| Operating margin as of 2026-07-30 | +17.5% | -500.0% | BIIB higher |
| ROE as of 2026-07-30 | +7.5% | -71.2% | BIIB higher |
| ROA as of 2026-07-30 | +4.7% | -64.5% | BIIB higher |
| Debt / equity as of 2026-07-30 | 0.34 | 0.00 | RLMD lower |
| Revenue growth (YoY) as of 2026-07-30 | +1.2% | n/a | |
| Revenue CAGR (3y) SEC XBRL | -0.9% | n/a | |
| Beta as of 2026-07-30 | 0.16 | 0.50 | |
| 1-year return as of 2026-07-27 close | +52.2% | +703.7% | RLMD higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.